Jagsonpal Pharmaceuticals Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Jagsonpal Pharmaceuticals Ltd filed with BSE on 04 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Jagsonpal reported a Q4 FY26 recovery with revenue up 10% year-on-year to Rs 64 crore and EBITDA up 9% to close to Rs 11 crore, while full-year FY26 revenue grew about 7% to Rs 287 crore. Management attributed the quarter's acceleration to improved MR productivity, field force retention, and outperformance versus the Indian Pharma Market. The board also announced a Rs 40 crore buyback at Rs 250 per share and a 200% dividend including a one-time special dividend of 75%.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue: INR64 crores (Q4 FY26)
p. 5
“revenue growing by 10% year-on-year to INR64 crores, supported by healthy demand momentum across key therapies and stronger execution”
Nirav Vora, page 5 of the filed PDF · View the filing
EBITDA: close to INR11 crores (Q4 FY26)
p. 5
“This translated into EBITDA growth of 9% year-on-year to close to INR11 crores, while maintaining stable margins at close to 16%, reflecting disciplined cost management and operating resilience”
Nirav Vora, page 5 of the filed PDF · View the filing
PAT: close to INR9 crores (Q4 FY26)
p. 5
“Profitability saw a sharper uptick with PAT rising to 31% year-on-year to close to INR9 crores and with a PAT margin expanding to approx. 14%”
Nirav Vora, page 5 of the filed PDF · View the filing
Revenue: INR287 crores (FY26)
p. 5
“For the full year, FY26 revenue grew by approx. 7% to INR287 crores and operating EBITDA stood at close to INR61 crores with the margin of approx. 21%”
Nirav Vora, page 5 of the filed PDF · View the filing
Profit from operations: close to INR45 crores (FY26)
p. 5
“At the profitability level, our profits from operations grew by 19% year-on-year to close to INR45 crores, reflecting a margin of approx. 16%”
Nirav Vora, page 5 of the filed PDF · View the filing
Cash position: over INR190 crores (as of 31 March 2026)
p. 5
“We also continue to maintain a strong balance sheet with a cash position of over INR190 crores”
Nirav Vora, page 5 of the filed PDF · View the filing
Net working capital cycle: close to 11 days (FY26)
p. 5
“Working capital remains well-managed with net working capital cycle at close to 11 days, reflecting our continued focus on financial discipline and prudent capital allocation”
Nirav Vora, page 5 of the filed PDF · View the filing
MAT sales growth: 12.2% (FY26 (MAT))
p. 4
“On a MAT basis, which is annual sales, the company has delivered 12.2% growth as per Pharmarack, outperforming the market by 3.6%”
Amrut Medhekar, page 4 of the filed PDF · View the filing
Quarterly growth vs industry: 14.2% vs 10.5% (Q4 FY26)
p. 4
“this momentum accelerated further in the last quarter, which is Quarter 4, where the growth reached 14.2% against the industry growth of 10.5%”
Amrut Medhekar, page 4 of the filed PDF · View the filing
Gross margin: 64.2% (FY26)
p. 9
“our full year gross margins are largely in line, there has been minor change, but it is more or less 64.2%”
Manish Gupta, page 9 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth vs IPM — 1.5x IPM growth · FY27 and beyond
stated firmly by Amrut Medhekar
p. 9
“we are certainly targeting a 1.5x of the pharma industry growth”
Amrut Medhekar, page 9 of the filed PDF · View the filing
FY27 growth guidance — 1.5x IPM growth · FY27
stated firmly by Amrut Medhekar
p. 7
“We continue to maintain that guidance, sir.”
Amrut Medhekar, page 7 of the filed PDF · View the filing
New product launches — approximately 9 to 10 · current year
stated as an aspiration by Amrut Medhekar
p. 8
“We intend to have similar number approximately 9 to 10 in this current year as well, in which half of it will be more of rejuvenating the older brands”
Amrut Medhekar, page 8 of the filed PDF · View the filing
Return ratios post-buyback — ROE from approx. 16% to 18%, ROCE from approx. 22% to close to 26%
stated firmly by Nirav Vora
p. 5
“This move is expected to have significant impact on our return ratios, with ROE increasing from approx. 16% to 18%, while ROCE shall improve from approx. 22% to close to 26%”
Nirav Vora, page 5 of the filed PDF · View the filing
New product announcement — first-in-India product launch announcement · May end or June first week
stated firmly by Amrut Medhekar
p. 15
“we'll make an announcement at the opportuned time, mostly either May end or June first week”
Amrut Medhekar, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the portfolio has few seasonal products and the growth was driven by operational strengthening.
Answered by Amrut Medhekar
Asked by Deepesh: How much of the Q4 improvement is structural versus seasonal?
p. 6
“what we see today is purely driven by operational strengthening, as well as some of the steps that we had taken in terms of our brand building and MR productivity improvement”
Amrut Medhekar, page 6 of the filed PDF · View the filing
Management said the main risk is macro-level, related to uncertain performance of new molecules in the market.
Answered by Amrut Medhekar
Asked by Deepesh: What is the biggest execution risk in achieving the targets given?
p. 6
“we may go over-aspirational on certain products, but yet we want to give them a full try with our heart and soul so that we are able to achieve them”
Amrut Medhekar, page 6 of the filed PDF · View the filing
Management explained that pharma growth is not capital intensive, and that cash is only needed for inorganic opportunities.
Answered by Manish Gupta
Asked by Deepesh: Why is the company distributing so much cash to shareholders instead of investing in growth?
p. 7
“Basically pharmaceutical industry for growth is not capital intensive. It is brand intensive.”
Manish Gupta, page 7 of the filed PDF · View the filing
Management broke down volume, new product and price growth contributions for both industry and Jagsonpal.
Answered by Amrut Medhekar
Asked by Sajal Kapoor: What quantitative thresholds should be tracked over the next two quarters to validate the turnaround?
p. 10
“our volume growth is reflected as 2% there. Our new product is matching the industry growth which is 3% plus. Our price growth is little shade higher, which is at around 6.5% to 7%”
Amrut Medhekar, page 10 of the filed PDF · View the filing
Management said there is no demand impact but some cost pressure on packaging material, which is expected to be manageable.
Answered by Manish Gupta
Asked by Avnish Parman: Is there any impact from Middle East disruptions on demand or raw material supply?
p. 12
“there is no impact of whatever is happening on the Middle East”
Manish Gupta, page 12 of the filed PDF · View the filing
Management said e-pharmacy contribution is currently insignificant.
Answered by Amrut Medhekar
Asked by Madhur Rathi: What percentage of revenue comes from e-pharmacies and on what commercial terms?
p. 13
“Currently the number is almost insignificant for us to have any mention of this in terms of supplies to these online pharmacies”
Amrut Medhekar, page 13 of the filed PDF · View the filing
Management said there is no fixed number in mind but expects payouts to be recouped from cash flow within the year.
Answered by Manish Gupta
Asked by Hitaindra Pradhan: Will the capital return strategy aim to keep net cash below roughly Rs 200 crore going forward?
p. 16
“I don't think we have a number in mind, but yes, we believe with the robustness of our cash flows which continues, we have adequate cash currently”
Manish Gupta, page 16 of the filed PDF · View the filing
Risks flagged
Execution risk from being over-aspirational on new product opportunities whose market performance is uncertain
p. 6
“One execution risk may be that we may go over-aspirational on certain products, but yet we want to give them a full try with our heart and soul so that we are able to achieve them”
Amrut Medhekar, page 6 of the filed PDF · View the filing
Cost pressure on packaging material and other inputs from global disruptions
p. 12
“there are certain pressures on the cost front, especially packaging material. Clearly all the vendors are seeing cost increases and they obviously while they are carrying certain inventories, they will be looking to pass on some of the cost increases”
Manish Gupta, page 12 of the filed PDF · View the filing
Macro-level risk affecting execution rather than organization-level risk
p. 6
“So I only see a macro risk happening for the organization”
Amrut Medhekar, page 6 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.